Phase II trial of clofarabine and daunorubicin as induction therapy for acute myeloid leukemia patients greater than or equal to 60 years of age
- 14 August 2013
- journal article
- research article
- Published by Elsevier in Leukemia Research
- Vol. 37 (11) , 1468-1471
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute (CA16056)
- Genzyme
- Leonard S. LuVullo Endowment for Leukemia Research
- Nancy C. Cully Endowment for Leukemia Research
- Dennis Szefel Jr. Endowment
- Babcock Family Endowment
- Heidi Leukemia Research Fund, Buffalo, NY
This publication has 14 references indexed in Scilit:
- Drug resistance: Still a daunting challenge to the successful treatment of AMLDrug Resistance Updates, 2012
- Therapeutic Advances in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2011
- Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNetBlood, 2010
- Prognostic Significance of, and Gene and MicroRNA Expression Signatures Associated With, CEBPA Mutations in Cytogenetically Normal Acute Myeloid Leukemia With High-Risk Molecular Features: A Cancer and Leukemia Group B StudyJournal of Clinical Oncology, 2008
- Clofarabine: Past, present, and futureLeukemia & Lymphoma, 2007
- Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or olderBlood, 2006
- Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutationsBlood, 2005
- Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2003
- A simple, robust, validated and highly predictive index for the determination of risk‐directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trialBritish Journal of Haematology, 1999
- Synthesis and biological activity of 2'-fluoro-2-halo derivatives of 9-.beta.-D-arabinofuranosyladenineJournal of Medicinal Chemistry, 1992